Racial differences in CD8
Adult
Black or African American
Aged
Breast Neoplasms
/ ethnology
CD8-Positive T-Lymphocytes
/ immunology
Case-Control Studies
Female
Follow-Up Studies
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Middle Aged
Prognosis
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
Survival Rate
White People
Women's Health
Young Adult
Breast cancer
CD8+
Disparities
Immune infiltrates
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
09 06 2020
09 06 2020
Historique:
received:
16
01
2020
accepted:
17
05
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
6
11
2020
Statut:
epublish
Résumé
African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been reported between Black and White women, and the tumor immune milieu could potentially drive racial differences in breast cancer etiology and outcome. We examined the association of CD8 Black women had a significantly higher percentage of high-grade, estrogen receptor (ER)-negative, and triple-negative tumors than White women and significantly higher CD8 Our data raise the possibility that distinct mechanisms of immune cell action may occur in different racial groups.
Sections du résumé
BACKGROUND
African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been reported between Black and White women, and the tumor immune milieu could potentially drive racial differences in breast cancer etiology and outcome.
METHODS
We examined the association of CD8
RESULTS
Black women had a significantly higher percentage of high-grade, estrogen receptor (ER)-negative, and triple-negative tumors than White women and significantly higher CD8
CONCLUSIONS
Our data raise the possibility that distinct mechanisms of immune cell action may occur in different racial groups.
Identifiants
pubmed: 32517730
doi: 10.1186/s13058-020-01297-4
pii: 10.1186/s13058-020-01297-4
pmc: PMC7285742
doi:
Substances chimiques
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Subventions
Organisme : NCI NIH HHS
ID : R01 CA10059
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA133264
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA151135
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA185623
Pays : United States
Références
Int J Cancer. 2014 Mar 15;134(6):1408-21
pubmed: 23996684
Cell. 2016 Oct 20;167(3):643-656.e17
pubmed: 27768888
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Breast Cancer Res Treat. 2011 Nov;130(2):635-44
pubmed: 21717106
Br J Cancer. 2013 Nov 12;109(10):2705-13
pubmed: 24129232
PLoS Genet. 2018 Jun 7;14(6):e1007368
pubmed: 29879116
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
J Am Coll Cardiol. 2005 Aug 2;46(3):464-9
pubmed: 16053959
J Clin Oncol. 2015 Mar 20;33(9):983-91
pubmed: 25534375
Am Soc Clin Oncol Educ Book. 2019 Jan;39:3-10
pubmed: 31099618
Oncotarget. 2015 May 10;6(13):11231-41
pubmed: 25868978
JAMA. 2006 Jun 7;295(21):2492-502
pubmed: 16757721
Adv Immunol. 2006;90:1-50
pubmed: 16730260
J Clin Oncol. 2009 Jul 20;27(21):3437-44
pubmed: 19470939
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
PLoS One. 2009;4(2):e4531
pubmed: 19225562
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
J Oncol. 2009;2009:871250
pubmed: 19865486
JAMA Surg. 2013 Jun;148(6):516-23
pubmed: 23615681
Breast Cancer Res Treat. 2017 Nov;166(2):559-568
pubmed: 28756535
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
JCI Insight. 2019 Oct 3;4(19):
pubmed: 31465302
Cancer Res. 2006 Sep 1;66(17):8327-30
pubmed: 16951137
J Immunother Cancer. 2019 Feb 6;7(1):34
pubmed: 30728081
Oncotarget. 2014 Jan 15;5(1):237-48
pubmed: 24368439
Cell. 2016 Oct 20;167(3):657-669.e21
pubmed: 27768889
Clin Chem. 2008 Jun;54(6):1027-37
pubmed: 18403563
Cancer. 2011 Apr 1;117(7):1542-51
pubmed: 21425155
JAMA Oncol. 2017 Dec 1;3(12):1654-1662
pubmed: 28472234
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):121-31
pubmed: 19124489
Cancer Causes Control. 2009 Feb;20(1):15-26
pubmed: 18704713
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
CA Cancer J Clin. 2019 May;69(3):211-233
pubmed: 30762872
Breast Cancer Res Treat. 2011 Nov;130(2):645-55
pubmed: 21717105
Breast Cancer Res Treat. 2019 May;175(1):247-259
pubmed: 30725384
Breast Cancer Res Treat. 2016 Jul;158(1):113-126
pubmed: 27283835
Cancer. 2007 Jul 15;110(2):403-11
pubmed: 17562557
Science. 2014 Sep 12;345(6202):1254665
pubmed: 25214635
Obesity (Silver Spring). 2009 Jul;17(7):1420-7
pubmed: 19197255
J Clin Oncol. 2015 Nov 1;33(31):3621-7
pubmed: 26371147
Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):470-8
pubmed: 26711328
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
Nat Rev Immunol. 2016 Oct;16(10):599-611
pubmed: 27526640
Oncol Rep. 2013 Jan;29(1):141-8
pubmed: 23076599